Intellin® is an intelligent remote management diabetes platform, with over 140,000 downloads so far this year. Having established themselves as an approved vendor with Big Pharma, they're now poised to scale the business globally and drive commercialisation.
- Over 140,000 downloads in 170 countries
- Designed for remote monitoring – healthcare team to patient – critical post COVID19
- A novel platform that uses clinical history to predict risk
- Gendius is an approved vendor for AstraZeneca Saudi Arabia
Since our last successful appearance on Crowdcube last year, intellin® has established itself as a growing presence in diabetes management. In the last three months, intellin® has been downloaded over 140,000 times by those seeking better management of diabetes.
The COVID-19 crisis has highlighted the need for remote home monitoring of patients. Dr Martin Marshall, (Chair, RCGP) said that ‘Having the technological capability to offer remote consultations, where appropriate, will be beneficial for general practice, the wider NHS and most importantly our patients, long after this pandemic has ended’. Intellin® has connection to over 150 medical devices and apps, and two-way communication with the Healthcare Professional via a secure dashboard leaves intellin® with the potential to play an important role going forward. We are part-way through a trial in a GP practice and are now ready to discuss our offering with the wider NHS. We are registered as an approved vendor with AstraZeneca in Saudi Arabia and aim to use this as a springboard to other opportunities.
We are now planning a £5m investment round to scale the business globally and drive commercialisation. We are keen to offer this opportunity to the Crowd who have already supported the business before we then target Venture Capital for the remaining funding.
Gendius is headed up by Rory Cameron (CEO) an experienced pharmaceutical and mHealth leader who has built and exited successful companies. Rory is passionate to ensure that Gendius operates at the highest ethical standards.
Co-founder Chris Genders is also a seasoned pharmaceutical industry professional, operating to director level. The original idea for intellin came from Chris's diagnosis of diabetes 15 years ago, and his passion is use mHealth and technology to help those with diabetes live better and understand their condition.
Chair Albert Nicholl has many years of experience in med tech industry and now spends his time as a coach and mentor for entrepreneurs. Further Board advisors include Charles Toomey, James Crossland and Dr Natasha Patel.
The motivation comes from a personal experience of just how hard diabetes can be. Many apps exist that tell you how you've been doing (the rear-view mirror) while intellin helps you understand the road ahead (sat-nav).
intellin has been proven as a capable remote monitoring platform and has been rated on the NHS backed Orcha platform which has driven greater engagement during the Covid crisis. Post COVID, we aim to develop the concept even further working alongside not only the NHS but private providers too.
We believe the current pandemic has identified the need for remote management of people with diabetes. Intellin is that solution.